Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu guides a discussion about biomarkers and some of the challenges and issues they create.

The Importance of Waiting for Biomarker Results in NSCLC

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share The Importance of Waiting for Biomarker Results in NSCLC

Sign up to save your podcasts

The Importance of Waiting for Biomarker Results in NSCLC

The Importance of Waiting for Biomarker Results in NSCLC

More shows like Lung Cancer Considered

Marketplace

NPR News Now

WSJ What’s News

NEJM This Week

JAMA Clinical Reviews

Lung Cancer Update

Research To Practice | Oncology Videos

The Daily

Up First from NPR

OncLive® On Air

The Journal.

Conversations in Lung Cancer Research

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

Lung Cancer Rx